Chordoma is a rare bone cancer which arises from undifferentiated notochordal remnants in the axial skeleton. It generally has slow-growing and locally aggressive behavior. This tumor is usually diagnosed by CT and MRI modalities and the role of SPECT/CT is still debated. It shows reduced or normal uptake of radioisotope on bone scanning and increased tracer uptake is infrequently reported. Here we present a 33-year-old man with complaint of low back pain and numbness of his right leg. The whole body bone scan showed relatively uniform radiotracer activity throughout the skeleton. A focal increased uptake in the second lumbar vertebra was noted on SPECT/CT images. SPECT/CT also demonstrated multiple lytic lesions in lumbar vertebrae. The lesions were proven to be chordoma on biopsy. Lumbar chordoma could be one of the differential diagnoses for lytic lesions of the vertebrae which show absent or minimal tracer uptake on bone scintigraphy and SPECT/CT imaging. Our case was unusual as the patient was very young for chordoma diagnosis and bone scan showed increased uptake adjacent to the involved vertebral lesion detected by SPECT/CT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701223 | PMC |
| http://dx.doi.org/10.22038/AOJNMB.2020.48929.1331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Chordoma is a rare, slow-growing notochordal neoplasm typical of adults. Less than 5% of the cases occur in children, where they are located at the skull base. Treatment involves surgical resection with or without radiotherapy.
View Article and Find Full Text PDFChallenging the giant: A case report on a huge sacrococcygeal chordoma and its radiological insights.
Radiol Case Rep
February 2025
Department of Psychiatry, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra 442001, India.
Sacral chordoma is a rare osseous tumor of malignant origin. Remnants of the notochord in the region of sacrum and coccyx is said to be the origin of these tumors. Patients generally have delayed presentation, which is responsible for larger tumor size.
View Article and Find Full Text PDFConventional Spinal Chordomas: Investigation of SMARCB1/INI1 Protein Expression, Genetic Alterations in Gene, and Clinicopathological Features in 89 Patients.
Cancers (Basel)
August 2024
Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
Article Synopsis
- Recent studies show a partial loss of SMARCB1/INI1 expression in skull base chordomas, suggesting potential treatment options for these tumors; this study focused on 89 patients with spinal chordomas.
- The analysis found that 41.6% of patients exhibited partial SMARCB1/INI1 loss, primarily due to a deletion on chromosome 22, with significant implications for tumor location and surgical outcomes.
- Key findings indicated that tumor location (specifically in the sacrococcygeal region) and adequate surgical margins were linked to better disease-free survival rates, highlighting important factors for patient prognosis.
Benign Notochordal Cell Tumours: Case Report and Literature Review.
Diagnostics (Basel)
June 2024
Institute of Diagnostic Radiology, Pauls Stradins Clinical University Hospital, LV-1002 Riga, Latvia.
Background: Benign notochordal cell tumours (BNCTs) represent a rare entity within the spectrum of bone neoplasms, which typically arise in the axial skeleton. Although these tumours are often benign, their diagnosis and management pose significant challenges due to their histological similarity to more aggressive lesions, such as chordomas. Understanding of the clinical behaviour, diagnostic nuances, and optimal management strategies for BNCTs continues to evolve.
View Article and Find Full Text PDFLumbar functional evaluation of pelvic bone sarcomas after surgical resection and spinal pelvic fixation: A clinical study of 304 cases.
Cancer Med
June 2024
Department of Musculoskeletal Tumor, People's Hospital, Peking University, Beijing, China.
Aims: We endeavored to introduce a novel scoring system (Lumbar Functional Index, LFI) capable of evaluating lumbar function in pelvic bone sarcoma patients who underwent surgical resection and spinal pelvic fixation, while simultaneously identifying the incidence, outcomes, and risk factors of lumbar function impairment among these populations.
Patients And Methods: A cohort of 304 primary bone sarcoma patients were recruited. The LFI was created based on the Oswestry Dysfunction Index (ODI) and Japanese Orthopaedic Association (JOA) scores.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!